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Abstract Monoclonal antibodies directed against proteins mod- 
ified with the major membrane lipid peroxidation product, 4- 
hydroxy-2-nonenal, have been established and characterized. The 
monoclonal antibodies specific for HNE-modified proteins were 
raised by immunizing mice with a HNE-keyhole limpet hemocy- 
anin conjugate. The resulting five monoclonal antibodies (mAbs 
HNEJ-1-5) recognized HNE-modified bovine serum albumin 
(BSA), but not native BSA in Western blot studies. Of the five 
mAbs, HNEJ-2 exhibited the highest affinity for HNE-modified 
proteins and a much higher affinity for the HNE-histidine adduct 
than the HNE-lysine or HNE-cysteine adducts, mAb HNEJ-2 
did not cross-react with proteins that had been treated with other 
aldehydes, such as 1-hexenal, 2-hexenal, 4-hydroxy-2-hexenal, 
2-nonenal, formaldehyde, or glutaraldehyde. These results sug- 
gest that the major epitope recognized by mAb HNEJ-2 is the 
Michael addition-type HNE-histidine adduct. 
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I. Introduction 
Ehrlich ascites tumor cells. HNE also exhibits genotoxic and 
mutagenic effects, as well as inhibitory effects on cell prolifera- 
tion [2]. In a model system using Ehrlich ascites tumor cells, 
more than 80% of HNE are metabolized to non-toxic com- 
pounds, either by oxidation or reduction, within 10 min after 
exposure. However, a fraction (approximately 1-6%) of HNE 
is covalently bound to proteins [3]. It has been proposed that 
HNE exerts the cytotoxic effects via its facile reactivity with 
proteins. We have previously established that the imidazole 
nitrogens of the histidine residue is one of the major targets of 
HNE reactivity, in addition to the e-amino group of the lysine 
residue and the sulfhydryl group of cysteine residue [4]. 
We have recently raised a polyclonal antibody against HNE- 
modified proteins, and showed that epitopes recognized by this 
polyclonal antibody are present in oxidized cultured hepato- 
cytes [5], atherosclerotic lesions of human aorta [6], renal prox- 
imal tubules of rats treated with a renal carcinogen, ferric 
nitrilotriacetate [7], and human renal cell carcinoma [8]. How- 
ever, polyclonal antibodies recognize multiple epitopes and 
have a limitation in the quantity that can be prepared. In the 
present study, we established and characterized five monoclo- 
hal antibodies (mAbs) specific for HNE-modified proteins. 
Reactive oxygen species (ROS) are involved in a diversity of 
biological phenomena, such as inflammation, mutagenesis, 
carcinogenesis, aging, atherosclerosis, and ischemia reperfu- 
sion injury [1]. Membrane lipids are one of the major targets 
of ROS, initiating the free radical chain reaction by lipid perox- 
idation [1]. In this process, a variety of aldehydes are generated 
as final products when lipid hydroperoxides break down. 
Among them, 4-hydroxy-2-nonenal (HNE) is an ~fl-unsatu- 
rated aldehyde that can be formed by peroxidation of co6- 
unsaturated fatty acids such as linoleic and arachidonic acids. 
In biological systems, HNE originates almost exclusively from 
phospholipid-bound arachidonic acid, and may be the most 
reliable marker of lipid peroxidation [2]. 
HNE exhibits various cytopathological effects, such as en- 
zyme inhibition, inhibition of DNA, RNA and protein synthe- 
sis, and induction of heat-shock proteins [2]. It is highly toxic 
to many types of cells, including hepatocytes, fibroblasts and 
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2. Materials and methods 
2.1. Materials 
The stock solution of trans-4-hydroxy-2-hexenal a d trans-4-hy- 
droxy-2-nonenal were prepared by acid treatment (1 mM HC1) of HNE 
diethylacetal, which was synthesized according to the procedure of De 
Montarby et al. [9]. The concentration f the HNE stock solution was 
determined by measurement of UV absorbance at 224 nm [10]. 2- 
Nonenal, 1-hexenal, glutaraldehyde, and formaldehyde were obtained 
from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Keyhole 
limpet hemocyanin (KLH) was obtained from Pierce (Rockford, IL). 
Horseradish peroxidase-linked anti-rabbit IgG immunoglobulin was 
obtained either from Dako (Kyoto, Japan) or Amersham (Little Chal- 
font, England). Enhanced chemiluminescence (ECL) immunoblotting 
detection reagents were obtained from Amersham. Bovine serum albu- 
min (BSA) was obtained from Intergen Co. (Purchase, NY). 2-Hexenal, 
N~-acetyl-L-histidine, N~-acetyl-L-lysine and glutathione were ob- 
tained from Sigma (St. Louis, MO). Protein concentration was meas- 
ured using the BCA protein assay reagent obtained from Pierce. 
2.2. Immunization 
The HNE-modified KLH (HNE KLH) immunogen was prepared 
by reacting KLH with HNE as previously described [5]. The HNE- 
modified BSA (HNE-BSA) was prepared by incubating 10 mg/ml of 
BSA with 1 mM HNE at 37°C for 2 h. 
HNE-KLH (100 ,ug/100/zl) was emulsified in an equal volume of 
Freund's complete adjuvant (Difco, Detroit, MI) and injected intraper- 
itoneally, subcutaneously and intramuscularly (1/2, 1/4 and 1/4 vol., 
respectively) tofemale BALB/c mice (7 weeks of age; Shizuoka Labora- 
tory Center, Shizuoka, Japan). After 4 and 8 weeks, booster injections 
in incomplete Freund's adjuvant (Difco) and without adjuvant, respec- 
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tively, were done. The antibody response in serum was monitored by 
Western blot and ELISA using BSA and HNE-BSA as the paired 
antigens. 
2.3. Monoclonal ntibody 
The fusion was performed by the use of 8-azaguanine-resistant mur- 
ine myeloma P3X63-Ag8.653 (653) cells at a ratio of 5 : 1 as previously 
described [10]. Culture medium was RPMI- 1640 in the presence of 10% 
fetal calf serum, 0.03% (w/v) L-glutamine, 0.0015% (w/v) 8-azaguanine 
and 2.5 x 10 7 M 2-mercaptoethanol. Screening was done by ELISA 
using BSA and HNE BSA as the coupled antigens, mAbs were purified 
by ammonium sulfate from ascites of nude mice (BALB/c, nu/nu, fe- 
male, 8 weeks of age) after intraperitoneal injections of 107 hybridoma 
cells as previously described [11]. Immunoglobulin subclass was deter- 
mined by a kit from Amersham. 
2.4. ELISA 
For monitoring antibody response and cloning hybridomas, 96-well 
microtiter plates were filled with 100 pl of either 1 mg/ml BSA or 
HNE BSA, and incubated at 4°C overnight. After three washes in PBS 
containing 1% BSA, 0.5% Tween 20, each well was filled with 200/~l 
PBS/BSA to block non-specific binding for 1 h at room temperature 
(RT). After three washes, 150pl of the serum (diluted 1 : 100) or culture 
supernatant (diluted 1:3) was added to each well and incubated t\)r 
1 h at RT. Pre-immune BALB/c mouse serum or isotype-matched 
irrelevant commercial mAb (Dako) was used as a negative control. 
After three washes, 200 gtl of peroxidase-conjugated anti-mouse lgG 
antiserum (1 : 1000) was added and incubated for an additional 1 h at 
RT. After washing, 100/gl of 0.05 M citrate buffer (pH 5.0) containing 
0.4 mg/ml of o-phenylenediamine (Wako, Osaka) and 0.015% H202 was 
added and incubated for several minutes at RT. The reaction was 
terminated by addition of 2 M sulfuric acid and was quantified by 
absorbance at490 nm with a microtiter plate reader (M-EMax; Molec- 
ular Devices, Menlo Park, CA). For studies of HNE specificity and 
competition, aldehyde-modified proteins and the haptens (HNE N- 
acetylhistidine, HNE-N-acetyllysine, and HNE-glutathione) were pre- 
pared and ELISA carried out as previously described [5]. 
2.5. Western blot analysis 
Western blot analyses were done using 12.5% SDS-PAGE gels as 
previously described [5]. The bands were visualized by ECL reagents 
and autoradiography. 
3. Results 
3.1. Hybridomas ecreting antibodies against HNE-modified 
proteins 
Spleen cells of the immunized mice were fused with 653 cells 
and seeded into 720 wells of microwell plates. By screening 320 
hybridoma colonies, 28 highly positive colonies (AHN E BSA/ 
ABSA > 20) were obtained. We selected 5 colonies 
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Fig. 1. Western blot analysis of mAbs HNEJ-1 5 (200/tg/m]) using 
BSA and HNE-BSA (25 pg each/lane). (A) BSA; (B) HNE BSA; (P) 
polyclonal antibody published in [5] (2 pg/ml) as a control. 1 5 corre- 
spond to mAbs HNEJ-1 5, respectively. 
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Fig. 2. ELISA study for the specificity of mAb HNEJ-2. Aldehyde- 
modified proteins were prepared by reacting protein (GAPDH) with 
1 mM aldehyde (1 M for glutaraldehyde and formaldehyde) in 50 mM 
sodium phosphate buffer (pH 7.2) for 2 h at 37°C. Refer to section 2 
for details. 
based on proliferating activity, and cloned 5 hybridomas by 
repeated limiting dilutions. The 5 cloned hybridomas were 
named H N E J-1-5, respectively. The culture medium of HNEJ-  
1, -3 and -4 was changed to CM-B (Sanko Pharmaceutical, 
Tokyo, Japan) to maintain high proliferating activity. 
3.2. Characterization of the mAbs 
All five antibodies were IgG1, x subtype. The specificity of 
each antibody was studied by Western blot analysis, mAbs 
HNEJ-1 5 (200/lg/ml) recognized HNE-BSA but not BSA by 
Western blot (Fig. 1). The order of affinity for HNE-BSA was 
(mAb HNEJ-2 > 1 = 3 -- 4 > 5). mAb HNEJ-2 was further 
characterization using ELISA. As shown in Fig. 2, mAb HNEJ-  
2 showed almost negligible reactivity with proteins that had 
been treated with other aldehydes, such as 2-nonenal, 2-he- 
xenal, 1-hexenal, 4-hydroxy-2-hexenal, formaldehyde, or glu- 
taraldehyde. 
3.3. Competition by HNE-amino acid adducts 
As shown in Fig. 3, among the HNE adducts (N-acetylhistid- 
ine, N-acetyllysine and HNE-glutathione) tested, only HNE-  
N-acetylhistidine inhibited the binding of antibody to the HNE-  
modified protein. In a control study the non-HNE-derivatized 
forms of these compounds exhibited no effect. 
4. Discussion 
We have previously prepared a polyclonal antibody against 
HNE-modif ied proteins [5] and demonstrated that the antibody 
is quite useful for the evaluation of ROS-induced amage both 
in vitro and in vivo [5-8]. This prompted us to raise monoclonal 
antibodies against HNE-modif ied proteins. We obtained 5 in- 
dependent mAbs by repeated cloning. All mAbs were highly 
specific for HNE-modif ied proteins. Indeed, mAb HNEJ-2 did 
not recognize 4-hydroxy-2-hexenal-modified proteins solely by 
the difference in carbon chain length. In addition, mAb HNEJ -  
2 did not recognize glutaraldehyde- or formaldehyde-modified 
proteins (Fig. 2). This is advantageous for the application of 
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Fig. 3. ELISA competition curves for mAb HNEJ-2. Refer to section 
2 for details. Assays used HNE-modified GAPDH as the absorbed 
antigen. The numbers on the abscissa indicate the concentration f
competitors when antibody was preincubated with competitors at4°C 
for 20 h. Competitors were as follows: e, HNE-N-acetylhistidine; 
A, HNE-N-acetyllysine; m, HNE glutathione; o, N-acetylhistidine; 
•, N-acetyllysine; t:, glutathione. B/B o, calculated as [experimental 
OD-background OD (no antibody)]/[total OD (no competi- 
tor) - background OD]. 
this mAb to immunohistochemistry since glutaraldehyde and 
formaldehyde are commonly used for morphological fixation. 
Further characterization of the other four mAbs are now in 
progress. The affinity of the mAbs for HNE-modified proteins 
was lower than that of the polyclonal antibody. This is proba- 
bly because the polyclonal antibody recognizes multiple epi- 
topes surrounding Michael adduct structures. 
By inhibition tests, we unexpectedly found that mAb HNEJ- 
2 has a much higher affinity for the HNE-histidine adduct han 
the HNE-lysine or HNE-cysteine adduct. This implies that 
there is a slight structural difference between Michael addition- 
type HNE-histidine adducts and HNE-lysine or HNE-cysteine 
adducts, and that the histidine-HNE adduct is a distinctive 
epitope for immune recognition. Based on our results it is 
stressed that the HNE-hist idine Michael addition reaction that 
we have previously reported [4] is unique and important in 
biology. 
In summary, we report for the first time the preparation and 
characterization f mAbs for HNE-modified proteins. We be- 
lieve that these mAbs will be useful for the evaluation of ROS- 
induced amage, not only in lipids in industry and food but also 
in membrane damage in various biological systems both in vitro 
and in vivo. 
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